Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Celcuity Inc. - Common Stock (NQ:CELC)

97.50 +3.50 (+3.72%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Celcuity Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Combination with Palbociclib and Endocrine Therapy for ER+ Advanced Breast Cancer (ABC) at the 2021 San Antonio Breast Cancer Symposium
78% ORR in 3rd line patients and 63% ORR overall in patients treated with three weeks on/one week off gedatolisib dosing schedule (Arm D) MINNEAPOLIS, MN / ACCESSWIRE / December 10, 2021 / Celcuity... 
From Celcuity Inc.
Via AccessWire
News headline image
Celcuity to Present at the 2021 San Antonio Breast Cancer Symposium
MINNEAPOLIS, MN / ACCESSWIRE / December 2, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating... 
From Celcuity Inc.
Via AccessWire
News headline image
Celcuity Appoints Michael Snitkovsky as VP of Program Management and David Bridge as VP of Quality Assurance and Process Development
MINNEAPOLIS, MN / ACCESSWIRE / November 29, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating... 
From Celcuity Inc.
Via AccessWire
News headline image
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
News headline image
Celcuity Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Provide Ibrance(R) (palbociclib) for Planned Phase 3 Clinical Trial
MINNEAPOLIS, MN / ACCESSWIRE / November 15, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating... 
From Celcuity Inc.
Via AccessWire
News headline image
Celcuity to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences
MINNEAPOLIS, MN / ACCESSWIRE / November 9, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating... 
From Celcuity Inc.
Via AccessWire
News headline image
Celcuity Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update
- On track to obtain FDA feedback and initiate a Phase 3 study for gedatolisib during the first half of 2022 - Will present updated Phase 1b data during a Spotlight Poster Discussion Session at the... 
From Celcuity Inc.
Via AccessWire
Topics Intellectual Property
News headline image
Celcuity Inc. Schedules Release of Third Quarter 2021 Financial Results and Webcast/Conference Call
MINNEAPOLIS, MN / ACCESSWIRE / October 29, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating... 
From Celcuity Inc.
Via AccessWire
News headline image
The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Entasis Announces Positive Data For Late-Stage Study Of SUL-DUR In... 
Via Benzinga
News headline image
Celcuity Announces Clinical Trial Collaboration with University of Rochester Wilmot Cancer Center and Puma to Study Patients with Breast Cancer Brain Metastases
From Celcuity Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 8, 2021 ↗
Upgrades UBS upgraded the previous rating for Northern Trust Corp (NASDAQ: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2021 ↗
Upgrades BMO Capital upgraded the previous rating for BRP Inc (NASDAQ: 
Via Benzinga
News headline image
Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
- Raised approximately $56.3 million of gross proceeds from a follow-on public offering of common stock in early July to provide funding for clinical development activities - After follow-on offering,... 
From Celcuity Inc.
Via AccessWire
News headline image
Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference
MINNEAPOLIS, MN / ACCESSWIRE / August 5, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating... 
From Celcuity Inc.
Via AccessWire
News headline image
Celcuity Inc. Schedules Release of Second Quarter 2021 Financial Results and Webcast
MINNEAPOLIS, MN / ACCESSWIRE / August 2, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic (CDx) and therapeutic strategy for... 
From Celcuity Inc.
Via AccessWire
News headline image
Celcuity to Participate in the William Blair Biotech Focus Conference
MINNEAPOLIS, MN / ACCESSWIRE / July 8, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating... 
From Celcuity Inc.
Via AccessWire
News headline image
58 Biggest Movers From Yesterday ↗
Gainers BSQUARE Corporation (NASDAQ: BSQR) shares jumped 206.9% to close at $8.04 on Tuesday on abnormally-high volume possibly amid increased attention from retail investors.... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers Cerevel Therapeutics Hldg (NASDAQ:CERE) stock moved upwards by 93.55% to $24.33 during Tuesday's regular session. As of 12:30 EST, this security is trading at... 
Via Benzinga
News headline image
35 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) shares jumped 111.5% to $26.58 after the company announced positive results from its Phase 1b clinical trial of CVL-231... 
Via Benzinga
News headline image
Why Celcuity Stock Is Crashing Today ↗
The clinical-stage biotech announced the pricing of a secondary stock offering. 
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers Cerevel Therapeutics Hldg (NASDAQ:CERE) shares moved upwards by 42.0% to $17.85 during Tuesday's pre-market session. The company's market cap stands at $2.... 
Via Benzinga
News headline image
22 Stocks Moving in Tuesday's Pre-Market Session ↗
Gainers Exela Technologies, Inc. (NASDAQ: XELA) rose 39% to $2.05 in pre-market trading after gaining over 5% on Monday. Marin Software Incorporated (NASDAQ: MRIN) rose 36.8% to... 
Via Benzinga
News headline image
Celcuity Announces Pricing of Follow-on Offering
MINNEAPOLIS, MN / ACCESSWIRE / June 28, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating... 
From Celcuity Inc.
Via AccessWire
Topics Regulatory Compliance
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers SCWorx (NASDAQ:WORX) shares rose ... 
Via Benzinga
News headline image
Celcuity Announces Launch of Follow-on Offering
MINNEAPOLIS, MN / ACCESSWIRE / June 28, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating... 
From Celcuity Inc.
Via AccessWire
Topics Regulatory Compliance
News headline image
The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
News headline image
45 Biggest Movers From Yesterday ↗
Gainers Marin Software Incorporated (NASDAQ: MRIN) shares surged 105.3% to close at $3.51 on Thursday after the company announced it has added the ability to manage Instacart Ads... 
Via Benzinga
News headline image
Celcuity Announces Appointment of Dr. Igor Gorbatchevsky as VP of Clinical Development and Jill Krause as VP of Clinical Operations
MINNEAPOLIS, MN / ACCESSWIRE / June 9, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating... 
From Celcuity Inc.
Via AccessWire
News headline image
The Daily Biotech Pulse: Biohaven, Bristol-Myers Squibb Snag FDA Approvals, Iterum UTI Drug Review On Track, Centessa Pharmaceuticals Debuts On Nasdaq ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 27) BioCryst Pharmaceuticals,... 
Via Benzinga
News headline image
Celcuity Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update
- Entered into worldwide licensing agreement with Pfizer to develop and commercialize gedatolisib, a first-in-class PI3K/mTOR inhibitor, in clinical development for breast cancer - Announced... 
From Celcuity Inc.
Via AccessWire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.